Outcomes Among Patients with EGFR-Mutant Metastatic NSCLC with and without Brain Metastases

被引：3
|
作者：
Nadler, E. [1 ]
Pavilack, M. [2 ]
Espirito, J. [3 ]
Baidoo, B. [3 ]
Fernandes, A. [2 ]
机构：
[1] Baylor Charles A Sammons Canc Ctr, Texas Oncol, Dallas, TX USA
[2] Astrazeneca, Gaithersburg, MD USA
[3] Mckesson Specialty Hlth, The Woodlands, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
NSCLC; brain metastases;
D O I：
10.1016/j.jtho.2018.08.380
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA08.06
引用
收藏
页码：S383 / S383
页数：1
相关论文
共 50 条
  • [41] Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma
    Gerber, Naamit K.
    Yamada, Yoshiya
    Rimner, Andreas
    Shi, Weiji
    Riely, Gregory J.
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Zhang, Zhigang
    Wu, Abraham J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (02): : 322 - 329
  • [42] Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters
    Estevinho, F.
    Felizardo, M.
    Fernandes, G.
    Figueiredo, A.
    Lopes, A.
    [J]. PULMONOLOGY, 2019, 25 (05): : 306 - 309
  • [43] A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases
    Lee, Jiyun
    Ahn, Myung-Ju
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) : E14 - E14
  • [44] Antacid and de novo brain metastases in EGFR-mutant NSCLC patients treated with first-line, first-generation EGFR-TKIs
    Chen, Y-M.
    Lin, M-C.
    Lai, C-H.
    Fang, W-F.
    Chang, H-C.
    Wang, C-C.
    Tseng, C-C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S132 - S132
  • [45] Clinical predictors of 5-year survival in patients with EGFR-mutant metastatic NSCLC treated with EGFR-TKIs.
    Lin, Jessica Jiyeong
    Cardarella, Stephanie
    Lydon, Christine A.
    Dahlberg, Suzanne Eleanor
    Jackman, David Michael
    Janne, Pasi A.
    Johnson, Bruce E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers.
    Kris, Mark G.
    Offin, Michael David
    Feldman, Daniel L.
    Ni, Ai
    Lai, Wei-Chu Victoria
    Arbour, Kathryn Cecilia
    Daras, Mariza
    Pentsova, Elena
    DeAngelis, Lisa Marie
    Beal, Kathryn
    Young, Robert J.
    Jordan, Emmet
    Arcila, Maria E.
    Jones, David Randolph
    Isbell, James M.
    Riely, Gregory J.
    Drilon, Alexander E.
    Yu, Helena Alexandra
    Li, Bob T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Real World Diagnosis and Treatment Outcomes in Patients with EGFR-Mutant Metastatic Lung Cancer
    Li, T.
    Ma, W.
    Tian, E.
    Li, Q.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1066 - S1067
  • [48] Vimentin expression status is a potential biomarker for brain metastasis development in EGFR-mutant NSCLC patients
    Teocharoen, Rattanawadee
    Ruangritchankul, Komkrit
    Vinayanuwattikun, Chanida
    Sriuranpong, Virote
    Sitthideatphaiboon, Piyada
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (02) : 790 - +
  • [49] Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
    Shi, Liang
    Tang, Junfang
    Tao, Hong
    Guo, Lili
    Wu, Weihua
    Wu, Hongbo
    Liu, Zichen
    Tong, Li
    Wu, Wei
    Li, Hongxia
    Meng, Qiyi
    Xu, Liyan
    Che, Nanying
    Liu, Zhe
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [50] Detection of EGFR mutations in cerebrospinal fluid of EGFR-mutant lung adenocarcinoma with brain metastases
    Shi, L.
    Liu, Z.
    Tang, J.
    Wu, H.
    Guo, L.
    Li, M.
    Tong, L.
    Wu, W.
    Tao, H.
    Wu, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S83 - S84
12345